LLY
Eli Lilly
Market cap$1.16T
Updated - ago
Eli Lilly (LLY) shares drifted down 0.39% to $1,273.50 over the past 24 hours, experiencing routine consolidation and profit-taking near record highs.1 The slight downward movement occurs as investors position themselves ahead of the company's upcoming Q3 2026 earnings report,2 following recent pipeline advancements and manufacturing expansion announcements.3
Eli Lilly and Company is a multinational pharmaceutical corporation headquartered in Indianapolis, Indiana, with roots tracing back to 1876. As one of the world's largest pharmaceutical manufacturers, Eli Lilly develops, produces, and markets a diverse portfolio of medications addressing major therapeutic areas including diabetes, oncology, immunology, cardiovascular disease, and neuroscience. The company is particularly renowned for its insulin products and innovative cancer treatments, serving patients and healthcare systems across more than 140 countries. Eli Lilly operates extensive research and development facilities dedicated to discovering new drug compounds and advancing existing therapies through clinical trials. The company maintains manufacturing operations globally to ensure reliable supply of its medications to hospitals, pharmacies, and healthcare providers worldwide. As a publicly traded corporation on the New York Stock Exchange, Eli Lilly's common stock represents fractional ownership in the company and its operations, making it a widely-held investment vehicle for those seeking exposure to the pharmaceutical and life sciences sector.